Lululemon sales flagged in the Americas during 2024 and mounting headwinds, most especially in the U.S., challenge growth ...

Shares of apparel retailer Lululemon Athletica sank early Friday as a soft outlook outweighed an estimate-topping fourth ...

India's art market is booming, and institutions are opening at a rapid pace. But insiders say the country needs even more ...

Oracle ORCL-4.37%decrease; red down pointing triangle results missed Wall Street expectations in the latest quarter, but the company offered an upbeat sales outlook ... thanks to growth in its ...

It was growing at a steady clip at the end of last year. The first quarter isn’t even over yet. And the jobs market was still in growth mode in January and February. It’s way too early to say ...

Oracle (ORCL) reported fiscal third-quarter sales that missed analysts’ expectations, but executives said they expect AI-driven growth in the coming fiscal year. The tech giant saw quarterly ...

The value of art sold at auctions globally fell by a third last year compared to 2023, with the Chinese market crashing by 63 per cent, newly figures show. Artprice, a France-based consultancy ...

In its latest housing market outlook, analysts from J.P. Morgan point out that existing inventory and home sales ... growth is still expected, but at a very subdued pace of 3% or less.

Gone are the days of endless record-breaking bids at art auctions, with the once-booming market spurred by speculator cash in decline since 2021. That has meant some high-end sellers have postponed or ...

Investors were optimistic about the potential for a lower interest rate environment ahead and the fact that such a backdrop could benefit high-growth ... sales in the U.S. comes from imports, and ...

Weakening demand at the global art collector level also feeds through to primary sales -- sales of work through galleries -- which affect artists' prices and income. Dewar said that her ...

Ipsen is a global biotechnology company headquartered in France that develops and commercializes medicines across three therapeutic areas: oncology, neuroscience, and rare diseases. Ipsen was ...